ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2012

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.

Galin V Michailov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.